Home » REGS » Page 2
  • Most effective drugs for obesity and its complications are semaglutide, tirzepatide, new European guideline says
  • Certain GLP-1 drugs are best for specific complications
  • The non-binding guideline emphasizes economic considerations in obesity treatment
Oct 2 (Reuters) – Novo Nordisk’s (NOVOb.CO)opens new tab and Eli Lilly’s (LLY.N)opens new tab blockbuster weight-loss drugs should be the first medicines doctors reach for to treat obesity and its complications, a major European medical association advised on Thursday.

Semaglutide, the active ingredient in Novo’s Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European Association for the Study of Obesity published in Nature Medicine.

Sign up here.

When a lesser degree of weight loss is required, other medications can be considered, including liraglutide, an older, less effective drug from the same class, naltrexone–bupropion, and phentermine-topiramate, the guideline says.

Novo shares were up 2.2% at 1007 GMT, outperforming European pharmaceuticals peers.

The EASO guidelines are non-binding on individual countries.

Semaglutide, tirzepatide, and other drugs from the class known as GLP-1 agonists are completely transforming care of obesity and its complications, coauthor Dr. Andreea Ciudin of Vall d’Hebron University Hospital in Barcelona said in a statement.

Although no treatment algorithm can replace the nuanced clinical judgment necessary for comprehensive patient care, the new guidelines can serve to support therapeutic decision-making in obesity, she said.

SPECIFIC DRUGS FOR SPECIFIC CONDITIONS

The guideline authors analyzed previous clinical trial results, evaluating the impact of medications on weight loss, their safety profile, and their effectiveness in the presence of specific complications.

For patients with the physical consequences of too much fatty, or adipose, tissue, tirzepatide should be considered as the first-line treatment for addressing obstructive sleep apnea, and semaglutide for those with knee osteoarthritis, the authors determined.

For patients with conditions linked with obesity-related metabolic and immune dysfunction, they recommend semaglutide as a first choice for those with a history of heart disease or stroke, tirzepatide for individuals with non-alcoholic fatty liver disease, and either tirzepatide or semaglutide for those with prediabetes or type 2 diabetes.

The class of drugs was originally developed to treat type 2 diabetes.

While the drugs are expensive and economic considerations are complex, the cost of not treating obesity at early stages, “thus enabling the progression to complications and end-organ damage, should be weighed equally in health policy and clinical decision-making,” the guideline authors wrote.

The management of obesity should not be limited to weight loss and its complications but should focus on enhanced mental well-being, physical fitness, social functioning, and overall health and quality of life as well, they also said.

Most of the newer medications have not been evaluated for the treatment of individual complications, they acknowledge.

Still, the authors say, the weight-loss effects have been strongly associated with improvements in various complications and there is growing potential for them to positively influence a broader range of disorders such as chronic kidney disease, neurodegenerative diseases, polycystic ovary syndrome, certain cancers, and mental health conditions.

“Given the rapid advances in the field of medications to treat obesity, EASO intends to update the present treatment algorithm regularly to incorporate the latest available evidence,” society President Professor Volkan Yumuk of Istanbul University-Cerrahpaşa said in a statement.

The American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society jointly advised in June that GLP-1 treatment must be accompanied by nutritional and lifestyle strategies.

“Although GLP‐1s alone can produce significant weight reduction and related health benefits, several challenges limit its long‐term success for individuals and populations,” including gastrointestinal side effects, risk of nutrient inadequacies, muscle and bone loss, high costs, frequent discontinuation, and weight regain,” the advisory said.

Reporting by Nancy Lapid; Editing by Caroline Humer, Bill Berkrot and Louise Heavens

Our Standards: The Thomson Reuters Trust Principles.opens new tab

What are the key mechanisms through which Wegovy (semaglutide) and Mounjaro/Zepbound (tirzepatide) contribute to weight loss?

European Doctors advocate Novo Nordisk and Eli Lilly Weight-Loss Drugs as Primary Obesity Treatment Options

The Shifting Paradigm in Obesity Management

European medical professionals are increasingly endorsing medications like Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Mounjaro (tirzepatide) – and now Zepbound (tirzepatide) – not merely as adjuncts to lifestyle interventions, but as primary treatment options for obesity. This represents a significant shift in how obesity, a chronic disease, is approached. For years, the focus remained heavily on diet and exercise, often with limited long-term success. Now, a growing body of clinical evidence supports the efficacy of these GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists in achieving significant and sustained weight loss.

This change isn’t about dismissing the importance of healthy habits; it’s about recognizing that obesity is a complex physiological condition often requiring pharmacological intervention. The conversation around weight management is evolving.

Understanding the Medications: Wegovy, Mounjaro & Zepbound

These drugs mimic naturally occurring hormones in the body, influencing appetite and food intake. Here’s a breakdown:

* Wegovy (Semaglutide): A GLP-1 receptor agonist originally approved for type 2 diabetes, Wegovy is now specifically indicated for chronic weight management.It works by slowing gastric emptying, increasing feelings of fullness, and reducing appetite. Clinical trials have demonstrated an average weight loss of around 15% in patients using Wegovy alongside lifestyle changes.

* Mounjaro/Zepbound (tirzepatide): A dual GIP and GLP-1 receptor agonist,tirzepatide has shown even more impressive results in clinical trials. Zepbound, the higher-dose version specifically for obesity, has demonstrated average weight loss exceeding 20% in clinical studies. It impacts both appetite and glucose regulation.

* Mechanism of Action: Both classes of drugs work on the brain’s appetite centers, reducing cravings and promoting satiety. They also improve insulin sensitivity, which is particularly beneficial for individuals with obesity and related metabolic disorders.

Why the Change in Approach? Evidence & Clinical Data

The advocacy from European doctors isn’t based on hype; it’s rooted in robust clinical data. Several factors contribute to this shift:

  1. High Obesity Rates: Europe, like much of the world, is facing an obesity epidemic. Customary methods haven’t adequately addressed the scale of the problem.
  2. Chronic Disease Recognition: Obesity is now widely recognized as a chronic, relapsing disease, not simply a matter of willpower. This understanding necessitates a more thorough and frequently enough pharmacological approach.
  3. Clinical Trial Results: Landmark trials, such as the SELECT trial with semaglutide demonstrating cardiovascular benefits in overweight/obese individuals without diabetes, have bolstered confidence in these medications.
  4. comorbidity reduction: these drugs have been shown to improve or resolve obesity-related comorbidities like type 2 diabetes, hypertension, sleep apnea, and non-alcoholic fatty liver disease (NAFLD). This holistic benefit is a key driver of physician support.

Benefits Beyond Weight Loss: A holistic Impact

The advantages of utilizing these medications extend far beyond the numbers on the scale.

* Improved Cardiovascular Health: Reduced risk of heart attack, stroke, and other cardiovascular events.

* Diabetes Management: Enhanced glycemic control and potential for diabetes remission.

* Reduced Joint Pain: Weight loss alleviates stress on joints, improving mobility and reducing pain.

* Enhanced Quality of Life: Improved physical function, mental well-being, and overall quality of life.

* Metabolic Syndrome Resolution: Advancement in multiple metabolic risk factors associated with metabolic syndrome.

Practical Considerations for Patients & Physicians

While these medications offer significant promise, they aren’t without considerations:

* Side Effects: Common side effects include nausea, vomiting, diarrhea, and constipation. These are typically mild to moderate and often subside with continued use.

* Cost & Access: The cost of these medications can be substantial, and access may be limited depending on healthcare systems and insurance coverage.

* Lifestyle Integration: These drugs are most effective when combined with lifestyle modifications,including a healthy diet and regular physical activity. They are not a “magic bullet.”

* Long-Term Use: Obesity is a chronic condition, and long-term medication use may be necessary to maintain weight loss.

* Monitoring: Regular monitoring by a healthcare professional is crucial to assess efficacy, manage side effects, and ensure overall health.

real-World Examples & emerging Trends

Several European countries are actively integrating these medications into their national obesity treatment guidelines. For exmaple, the UK’s National Health Service (NHS) has begun offering Wegovy to eligible patients through a structured weight management program. Denmark has also seen widespread adoption.

Furthermore,research is ongoing to explore the potential of combination therapies and personalized treatment approaches based on individual patient characteristics.The future of obesity treatment is highly likely to involve a more tailored and multifaceted approach,with medications playing a central role.

Addressing Concerns & Misconceptions

There’s been some public debate surrounding the use of these drugs, with concerns about potential rebound weight gain after discontinuation. While this is a valid concern, studies suggest that maintaining lifestyle changes after stopping medication can mitigate this risk. It’s crucial to have open and honest conversations with patients about

0 comments
0 FacebookTwitterPinterestEmail


CDC Director Ousted Weeks after Senate Confirmation amid Policy Conflicts

Washington D.C. – In a stunning turn of events, Dr. Susan Monarez has been dismissed from her role as Director of the Centers for Disease Control and Prevention (CDC) just weeks after her confirmation by the Senate. The White House revealed the decision on August 27th, citing basic disagreements over the direction of public health initiatives. This abrupt removal follows a period of mounting tension surrounding vaccine policies and internal conflict within the agency.

Policy Shifts and Rising tensions

The dismissal of Dr. monarez comes after Health Secretary Kennedy initiated important changes to the nation’s vaccine approach in May. These alterations included the suspension of COVID-19 vaccine recommendations for pregnant individuals and healthy children. Furthermore, Secretary Kennedy dissolved the CDC’s external Vaccination Implementation Advisory Committee, replacing experienced vaccine specialists with individuals reported to be critical of vaccine efficacy.

White House Justification and Contradictory Statements

White House Press Secretary Desai stated that the management was not aligned with a previous presidential platform focused on nationwide health improvement. desai confirmed that Dr. Monarez was relieved of her duties after declining a request to resign. However, a legal representative for Dr. Monarez vehemently denied these claims, asserting that she had not offered to resign and that she was unfairly targeted for refusing to endorse what thay described as “unscientific guidelines.”

Wave of Resignations at the CDC

Dr. Monarez’s departure is part of a broader exodus of leadership within the CDC. Dr. Wholey, the agency’s Chief Medical Officer, and Dr. Daskarakis, Director of the Center for Vaccination and Respiratory Diseases, have both resigned. Their resignation letters, verified by Reuters, cited concerns over the spread of misinformation, attacks on scientific integrity, the politicization of public health, and proposed cuts to the CDC’s funding and authority. Additional resignations include Jernigan, director of the Emerging Zoonotic Diseases Center, and Leiden, director of the CDC Public Health Data, Surveillance and Technology, according to NBC News reports.

Impact on Public Health Trust

These events raise significant questions about the stability and independence of the nation’s leading public health agency. A recent Pew Research Center study conducted in July 2025 indicated that public trust in the CDC has declined by 15% over the past year, largely attributed to perceived political interference and inconsistent messaging. Pew Research Center

Did You Know? The CDC was established in 1946 as the Communicable Disease Center,initially focused on combating malaria and typhus.

Executive Position Date of Departure
Susan Monarez CDC Director August 27, 2025
Dr. Wholey Chief Medical Officer August 27, 2025
Dr. Daskarakis Director, Center for Vaccination & Respiratory Diseases August 27, 2025
Jernigan Director, Emerging Zoonotic Diseases Center August 27, 2025
Leiden Director, Public Health Data, Surveillance & Technology August 27, 2025

Pro tip: Stay informed about public health recommendations by consulting multiple credible sources, including the World Health Organization (WHO) and your healthcare provider.

The Importance of an Independent CDC

A fully independent and adequately funded CDC is crucial for protecting public health. The agency’s ability to respond effectively to emerging threats,such as novel viruses or widespread outbreaks,relies on its scientific expertise,data-driven decision-making,and the trust of the public. Political interference and attempts to undermine scientific consensus can severely compromise these capabilities.

Frequently Asked Questions About the CDC Leadership Changes

  • What caused the dismissal of the CDC Director? The White House cited disagreements over public health policy, particularly regarding vaccine recommendations.
  • What is the role of the CDC’s advisory committees? These committees provide expert guidance to the CDC on critical public health issues, such as vaccination strategies.
  • How does public trust impact the CDC’s effectiveness? Public trust is essential for the accomplished implementation of public health measures, such as vaccination campaigns.
  • What are the concerns about the recent changes at the CDC? Concerns center on potential political interference, the spread of misinformation, and the erosion of scientific integrity.
  • Where can I find reliable information about public health? Refer to credible sources like the World Health Organization (WHO) and the CDC’s official website.
  • What impact could these changes have on future public health crises? Reduced trust and compromised expertise could hinder the nation’s response to future outbreaks and health emergencies.
  • Is the CDC still a reliable source of information? While facing challenges, the CDC remains a critical resource, but it’s essential to critically evaluate information and consult multiple sources.

What are your thoughts on the recent changes at the CDC? Do these events raise concerns about the future of public health in the United States? share your opinions in the comments below.


How might the dismissal of Dr. Monarez and the conflict with the Health and welfare Minister impact public trust in the CDC and other public health agencies?

US Governance Dismisses CDC Director, Clashes with Health and Welfare Minister Within First Month in office

The Sudden Departure of Dr. Susan Monarez

In a stunning development, Dr. Susan Monarez was abruptly removed from her position as Director of the US Centers for Disease Control and Prevention (CDC) just weeks into her tenure. The dismissal, confirmed on August 27, 2025, has sent ripples through the public health community and sparked concerns about political interference in scientific decision-making. This event coincides with reported clashes between the administration and Health and Welfare Minister, highlighting a growing tension within the government regarding public health strategies. The situation raises questions about the future of US health policy and the independence of crucial agencies like the CDC.

Timeline of Events: A Rapidly Escalating Situation

The sequence of events leading to Dr. Monarez’s ousting unfolded quickly:

  1. Appointment & Initial Optimism: Dr. Monarez was appointed to the CDC directorship with broad support from public health experts, promising a renewed focus on data-driven decision-making.
  2. Early Policy Disagreements: Within weeks, disagreements surfaced between Dr. Monarez and the administration regarding vaccine rollout strategies and public health messaging.
  3. senior Leader Resignations: Several senior CDC leaders reportedly resigned in protest, signaling deep dissatisfaction with the direction being taken.
  4. Dismissal Confirmed: The White House confirmed Dr. Monarez’s removal on August 27th, citing a need for “leadership aligned with the administration’s priorities.”
  5. Ministerial Conflict: Reports indicate a direct conflict between the Health and Welfare Minister and Dr. Monarez regarding the handling of emerging infectious disease threats.

The Core of the Dispute: Vaccine Policy and Public Health Messaging

The primary source of conflict appears to center around vaccine policies and the communication of public health information. Sources suggest dr. Monarez advocated for a more aggressive and targeted vaccine campaign, emphasizing the importance of reaching vulnerable populations. This reportedly clashed with the administration’s approach, which some critics describe as prioritizing political considerations over scientific recommendations.

Vaccine Hesitancy: The administration’s messaging has been accused of inadvertently fueling vaccine hesitancy, a growing concern for public health officials.

Data Clarity: Dr. Monarez reportedly pushed for greater transparency in the release of CDC data, a move that was resisted by some within the administration.

Emergency Preparedness: Concerns have been raised about the administration’s preparedness for future public health emergencies, with Dr. Monarez advocating for increased funding and resources.

Impact on Public Health Infrastructure

The sudden removal of a CDC director and the resignation of senior leaders can have a significant and detrimental impact on the nation’s public health infrastructure.

Loss of Expertise: the departure of experienced professionals creates a void in leadership and expertise at a critical time.

Erosion of Trust: Political interference in scientific decision-making can erode public trust in health agencies and undermine public health efforts.

Delayed Response to Threats: Instability within the CDC can delay the response to emerging health threats, potentially leading to more severe outbreaks.

Impact on Disease Control: Long-term consequences could include setbacks in efforts to control chronic diseases and prevent future pandemics.

The Role of the Health and Welfare Minister

The reported clashes between the administration and the Health and Welfare Minister add another layer of complexity to the situation. While details remain scarce, sources suggest the Minister advocated for a different approach to public health policy than dr.Monarez, further exacerbating the tensions within the government. The Minister’s stance on issues like mask mandates, social distancing guidelines, and vaccine requirements is under scrutiny.

Potential Consequences and Future Outlook

The dismissal of Dr. Monarez and the ongoing conflict within the administration raise serious concerns about the future of public health in the United States.

Increased Political Polarization: The situation is highly likely to further politicize public health issues, making it more tough to reach consensus on critical policies.

Challenges in Pandemic Preparedness: The instability within the CDC could hinder efforts to prepare for future pandemics and other public health emergencies.

need for Independent Oversight: Calls for greater independent oversight of the CDC and other public health agencies are likely to intensify.

* Focus on Public Health Leadership: The event underscores the importance of strong,independent leadership at the CDC and other key health agencies.

Sources:

Bloomberg: https://www.bloomberg.com/news/articles/2025-08-27/cdc-director-ousted-weeks-into-her-tenure-washington-post-says

0 comments
0 FacebookTwitterPinterestEmail

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.